Sutro Biopharma Announces Oral Presentation at ASCO 2023

- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab...

Related Keywords

United States ,Hebron ,Israel General ,Israel ,Chicago ,Illinois ,Canada ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,American ,Astellas Pharma ,Anne Borgman ,Anniej Chang ,Sutro Biopharma ,Bristol Myers Squibb ,Luveltamab Tazevibulin ,Amy Bonanno ,Exchange Commission ,Hebron Institute Of Oncology ,Solebury Strategic Communications ,Sutro Biopharma Inc ,American Society Of Clinical Oncology ,Hebron University Hospital ,Clinical Oncology ,Annual Meeting ,Principal Investigator ,Ana Oaknin ,Gynecological Tumor Unit ,Attending Physician ,Principal Clinical Investigator ,Gynecological Malignancies Group ,Hebron Institute ,Tumor Proportion Score ,Chief Medical ,South San Francisco ,Private Securities Litigation Reform Act ,Fast Track ,Nasdaq Stro ,Nc ,